LITERATURE
原始候选快照
v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。
| 论文 | 标识 | 日期 | 入排置信度 | 入排依据 | KM 状态 |
|---|---|---|---|---|---|
| Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk.N Engl J MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40337982无 PMCID | 2025-Jul-03 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.N Engl J MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40353578无 PMCID | 2025-Jul-03 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Structured Exercise after Adjuvant Chemotherapy for Colon Cancer.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40450658无 PMCID | 2025-Jul-03 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Achievement of long-term treatment goals in upadacitinib-treated patients with moderately to severely active ulcerative colitis: a post hoc analysis of phase 3 trial data.J Crohns Colitis疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:Graphical Abstract:非 KM 图;Figure 1.:非 KM 图;Figure 2.:非 KM 图;Figure 3.:AI 判定为 other;Figure 4.:生活质量量表图。 | PMID 40488552PMC12260494 | 2025-Jul-03 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Impact of mirikizumab treatment on fatigue in patients with moderately to severely active Crohn's disease: results from the phase 3 VIVID-1 study.J Crohns Colitis已检查 4 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:森林图/亚组分析图;Figure 3:生活质量量表图;Figure 4:AI 判定为 other。 | PMID 40491246PMC12231548 | 2025-Jul-03 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40532178无 PMCID | 2025-Jul-03 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Immune correlates analysis of mRNA-1345 RSV vaccine efficacy clinical trial.Nat Commun | PMID 40610413PMC12229610 | 2025-Jul-03 | 0.98 | 未发现恶性肿瘤人群证据。 | 已完成 |
| Efficacy and safety of Tafolecimab in Chinese patients with type 2 diabetes and hypercholesterolemia: a post-hoc analysis of pooled data from three phase 3 trials.Cardiovasc DiabetolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40611077PMC12224514 | 2025-Jul-03 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Seltoplasmid promotes ulcer healing versus placebo for treating patients with chronic limb-threatening ischemia: HOPE CLTI-2 trial.Mol Ther | PMID 40221835PMC12266034 | 2025-Jul-02 | 0.98 | 未发现恶性肿瘤人群证据。 | 已完成 |
| Survival and Quality of Life After Isolated Hepatic Perfusion With Melphalan as a Treatment for Uveal Melanoma Liver Metastases: Final Results From the Phase III Randomized Controlled Trial SCANDIUM.Ann Surg | PMID 38420778PMC12140551 | 2025-Jul-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| A minimal clinically important difference for the sleep inertia visual analog scale in idiopathic hypersomnia.J Clin Sleep Med入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 40135693PMC12225259 | 2025-Jul-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Ozoralizumab shows effectiveness regardless of baseline RF and ACPA titres in patients with RA: a post hoc analysis of the OHZORA trial.Rheumatology (Oxford)入排复审未纳入:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | PMID 40139716PMC12212905 | 2025-Jul-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Sex differences in blood pressure lowering of initial treatment with ultra-low dose combination therapy versus monotherapy. A secondary analysis of QUARTET.J Hypertens已检查 1 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 other。 | PMID 40178246PMC12144527 | 2025-Jul-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Phase 3 randomized study of physician choice vs metronomic chemotherapy in platinum refractory/ineligible head and neck cancer in palliative setting with survival outcomes.Cancer Lett疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40209850无 PMCID | 2025-Jul-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Randomized Study of Metformin and Intensive Lifestyle Intervention on Cancer Incidence over 21 Years of Follow-up in the Diabetes Prevention Program.Cancer Prev Res (Phila)已检查 4 张 PubMed Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:森林图/亚组分析图。 | PMID 40243198PMC12213222 | 2025-Jul-01 | 0.90 | The study is a Phase III randomized trial with a drug intervention and a time-to-event primary endpoint (cancer incidence, reported with HR). However, it is not an oncology trial for human malignant neoplasm; it is a primary prevention study in a diabetes population where cancer incidence is a safety or secondary outcome, not a treatment efficacy endpoint for an existing malignancy. Therefore, it does not meet the specific oncology cohort inclusion criteria. | 无 KM 图 |
| INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.Clin Cancer Res疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Figure 1.:非 KM 图;Figure 2.:森林图/亚组分析图;Figure 3.:非 KM 图。 | PMID 40300079PMC12209814 | 2025-Jul-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Ivarmacitinib for Moderate to Severe Atopic Dermatitis in Adults and Adolescents: A Phase 3 Randomized Clinical Trial.JAMA Dermatol已检查 2 张 PubMed Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图;Figure 2:AI 判定为 other。 | PMID 40305055PMC12044538 | 2025-Jul-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Roflumilast Foam, 0.3%, for Psoriasis of the Scalp and Body: The ARRECTOR Phase 3 Randomized Clinical Trial.JAMA Dermatol已检查 3 张 PubMed Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other。 | PMID 40332898PMC12060019 | 2025-Jul-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Quantitative Muscle Magnetic Resonance Outcomes in Patients With Duchenne Muscular Dystrophy: An Exploratory Analysis From the EMBARK Randomized Clinical Trial.JAMA Neurol已检查 3 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other。 | PMID 40354061PMC12070283 | 2025-Jul-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Comparison of Consolidation Strategies for Pediatric Patients With Acute Myeloid Leukemia: Results of the Randomized GATLA 8-LMA-P'07 Trial.J Pediatr Hematol Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40367210无 PMCID | 2025-Jul-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Dexmedetomidine- or Clonidine-Based Sedation Compared With Propofol in Critically Ill Patients: The A2B Randomized Clinical Trial.JAMA已检查 4 张 PubMed Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:森林图/亚组分析图。 | PMID 40388916PMC12090071 | 2025-Jul-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| ctDNA and Recurrence Risk for Adjuvant De-Escalation in HPV-Positive Oropharyngeal Carcinoma: A Secondary Analysis of the DART Phase 3 Randomized Clinical Trial.JAMA Otolaryngol Head Neck Surg疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40402484PMC12100506 | 2025-Jul-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Extent of coronary artery disease and clinical outcomes with ticagrelor monotherapy versus aspirin after coronary artery bypass grafting: insights from the TiCAB trial.Eur J Cardiothorac Surg已检查 4 张 PubMed Figure,均未识别为 KM 图:captionless-figure:AI 判定为 other;Figure 1:AI 判定为 other;Figure 2:森林图/亚组分析图;Figure 3:AI 判定为 other。 | PMID 40411761PMC12212761 | 2025-Jul-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Association of Hospitalizations With Randomized Glycemia-Lowering Treatment in GRADE.Diabetes Care | PMID 40424051PMC12178615 | 2025-Jul-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 已完成 |
| Chemoradiotherapy and Local Excision vs Total Mesorectal Excision in T2-T3ab, N0, M0 Rectal Cancer: The TAUTEM Randomized Clinical Trial.JAMA Surg | PMID 40434784PMC12120676 | 2025-Jul-01 | 0.90 | The trial is a Phase III randomized controlled trial in oncology with human patients and time-to-event efficacy endpoints (OS, DFS). However, the experimental intervention (chemoradiotherapy + local excision) and the control intervention (total mesorectal excision) are both non-drug-only treatments (radiotherapy and/or surgery). No drug-containing intervention is explicitly reported, which is a required criterion for eligibility. | 已完成 |
| INTEGRATE pooled phase 2/3 results are robust to postprogression switching and the winner's curse.JNCI Cancer Spectr疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:Figure 1.:森林图/亚组分析图;Figure 2.:森林图/亚组分析图。 | PMID 40455046PMC12212049 | 2025-Jul-01 | 0.95 | Eligibility criteria for oncology, human, randomized, phase3_or_definitive, time_to_event, and original_result are met. However, the required criterion of a drug-containing intervention is not explicitly established from the provided metadata (title, abstract, and publication details). The record describes a randomized Phase 3 trial with a key secondary time-to-event endpoint, but does not specify the therapeutic agent (drug, biologic, etc.) under evaluation. Therefore, it cannot be included. | 无 KM 图 |
| Evaluating the Efficacy of MamaLift Plus Digital Therapeutic Mobile App for Postpartum Depression (SuMMER): Randomized, Placebo-Controlled Pivotal Trial.J Med Internet Res已检查 1 张 PMC Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图。 | PMID 40549508PMC12264441 | 2025-Jul-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Quality comparison of mediastinal lymph node dissection between video-assisted thoracic surgery and open thoracotomy: a supplementary analysis of the phase 3 Japan Clinical Oncology Group 1413 trial†.Eur J Cardiothorac SurgPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40578313无 PMCID | 2025-Jul-01 | 0.95 | The study is a surgical technique comparison (VATS vs. open thoracotomy) from a Phase III randomized trial. It lacks a drug-containing intervention and its primary endpoint (N2 upstaging) is not a time-to-event efficacy endpoint (OS, PFS, etc.). Therefore, it is ineligible for this cohort. | 无 KM 图 |
| Bowel urgency in ulcerative colitis: effect of baseline urgency and change in urgency in response to mirikizumab.J Patient Rep Outcomes已检查 5 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 other;Fig. 2:AI 判定为 other;Fig. 3:AI 判定为 other;Fig. 4:AI 判定为 other;Fig. 5:AI 判定为 other。 | PMID 40591171PMC12214185 | 2025-Jul-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Levosimendan for postoperative subclinical heart failure after noncardiac surgery: a randomized, double-blinded, phase III trial.Nat Commun已检查 3 张 PubMed Figure,均未识别为 KM 图:Fig. 1:CONSORT/入组流程图;Fig. 2:AI 判定为 other;Fig. 3:AI 判定为 other。 | PMID 40593481PMC12219076 | 2025-Jul-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Quality of life and patient reported outcomes in the UK Mammo-50 randomised trial of annual versus less frequent mammographic surveillance in people with breast cancer aged 50 years and over.Health Qual Life Outcomes已检查 6 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 other;Fig. 2:AI 判定为 other;Fig. 3:AI 判定为 other;Fig. 4:AI 判定为 other;Fig. 5:AI 判定为 other;另有 1 张未列出。 | PMID 40598487PMC12220118 | 2025-Jul-01 | 0.85 | The record describes a Phase III randomized trial in oncology, but it is a quality-of-life sub-study focused on patient-reported outcomes, not a time-to-event efficacy endpoint. Additionally, the intervention is mammographic surveillance, not a drug-containing intervention. | 无 KM 图 |
| Safety and Efficacy of Switching SAR341402 Insulin Aspart and Originator Insulin Aspart vs Continuous Use of Originator Insulin Aspart in Adults With Type 1 Diabetes: The GEMELLI X Trial.J Diabetes Sci TechnolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 38420944PMC11571405 | 2025-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Impact of an SMS intervention to support type 2 diabetes self-management: DiabeText clinical trial.Br J Gen Pract已检查 1 张 PubMed Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图。 | PMID 39362693PMC11755587 | 2025-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Predictive Value of the nProfiler 1 Assay for the Efficacy of Adjuvant S-1-Based Doublet Chemotherapy in Stage III Gastric Cancer: A Post-Hoc Analysis of a Randomized Phase III Trial.Cancer Res Treat | PMID 39529388PMC12263233 | 2025-Jul | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 已完成 |
| Effect of Dupilumab on Health-Related Quality of Life and Respiratory Symptoms in Patients With COPD and Type 2 Inflammation: BOREAS and NOTUS.ChestPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 39894389无 PMCID | 2025-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Six Injections of Modified Adjuvanted PQ Grass Is Effective and Well-Tolerated in a Pivotal Phase III Trial.Allergy已检查 3 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:CONSORT/入组流程图;FIGURE 2:AI 判定为 other;FIGURE 3:森林图/亚组分析图。 | PMID 39905623PMC12261879 | 2025-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Anatomic Control with Faricimab versus Aflibercept in the YOSEMITE/RHINE Trials in Diabetic Macular Edema.Ophthalmol Retina | PMID 39914485PMC13218204 | 2025-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 已完成 |
| Safety and efficacy of repeat ivermectin mass drug administrations for malaria control (RIMDAMAL II): a phase 3, double-blind, placebo-controlled, cluster-randomised, parallel-group trial.Lancet Infect Dis | PMID 39919778PMC13273608 | 2025-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 已完成 |
| Induction of immune tolerance in living related human leukocyte antigen-matched kidney transplantation: A phase 3 randomized clinical trial.Am J TransplantPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 39922283无 PMCID | 2025-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Differential associations of somatic and cognitive-affective symptoms of depression with inflammation and insulin resistance: cross-sectional and longitudinal results from the Emotional Distress Sub-Study of the GRADE study.DiabetologiaPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 39951058PMC12176517 | 2025-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Population Pharmacokinetics of Fruquintinib, a Selective Oral Inhibitor of VEGFR -1, -2, and -3, in Patients with Refractory Metastatic Colorectal Cancer.J Clin Pharmacol入排复审未纳入:The report is a pharmacokinetic analysis derived from Phase I/Ib studies and a Phase III trial (FRESCO-2). While it involves a definitive randomized trial, the study's outcomes are pharmacokinetic parameters (e.g., clearance, half-life, covariate effects), not survival, progression, or other efficacy endpoints required for inclusion. | PMID 39969131PMC12202196 | 2025-Jul | 0.85 | The report is a pharmacokinetic analysis derived from Phase I/Ib studies and a Phase III trial (FRESCO-2). While it involves a definitive randomized trial, the study's outcomes are pharmacokinetic parameters (e.g., clearance, half-life, covariate effects), not survival, progression, or other efficacy endpoints required for inclusion. | 无 KM 图 |
| Efficacy and safety of patiromer for hyperkalemia: a randomized, placebo-controlled phase 3 study.Clin Exp Nephrol入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 39976633PMC12204919 | 2025-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Oral treatment of Whipple's disease with doxycycline and hydroxychloroquine versus intravenous therapy with ceftriaxone followed by oral trimethoprim-sulfamethoxazole in Germany: a phase 2/3, prospective, open-label, randomised, controlled, non-inferiority trial.Lancet Infect DisPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 39978372无 PMCID | 2025-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial.Lancet Infect DisPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40015292无 PMCID | 2025-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| First-Line Lorlatinib Versus Crizotinib in Asian Patients With Advanced ALK-Positive NSCLC: Five-Year Outcomes From the CROWN Study.J Thorac Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40024442无 PMCID | 2025-Jul | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Phase 2-3 Trial: Prevention of the Progression to Moderate and Severe COVID-19 in SARS-CoV-2-Infected Non-Hospitalized Adults With Inhaled siRNA-Based MIR 19.AllergyPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40028836无 PMCID | 2025-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Deucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trials.J Eur Acad Dermatol Venereol | PMID 40045918PMC12188513 | 2025-Jul | 0.95 | Study is a Phase 3 randomized trial of deucravacitinib in plaque psoriasis (non-oncology) with drug intervention and original results, but lacks a primary/key secondary time-to-event efficacy endpoint as required for the cohort. | 已完成 |
| Sofpironium topical gel, 12.45%, for the treatment of axillary hyperhidrosis: Pooled efficacy and safety results from 2 phase 3 randomized, controlled, double-blind studies.J Am Acad DermatolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40054501无 PMCID | 2025-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Mineralocorticoid Receptor Antagonism with Finerenone: A New Era in the Management of Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction.Am J Cardiovasc Drugs已检查 1 张 PubMed Figure,均未识别为 KM 图:Fig. 1:森林图/亚组分析图。 | PMID 40055303PMC12228588 | 2025-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Gut Microbiota in Advanced NSCLC Receiving Chemoimmunotherapy: An Ancillary Biomarker Study From the Phase III Trial JCOG2007 (NIPPON).J Thorac Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40058642无 PMCID | 2025-Jul | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |